Advances in peritoneal dialysis. Conference on Peritoneal Dialysis最新文献

The V2 receptor antagonist tolvaptan has been approved for volume control in heart-failure patients in Japan. Tolvaptan increases renal blood flow, and so the present study was designed to ascertain whether tolvaptan could be a useful diuretic for volume control without reducing residual renal function (RRF) in peritoneal dialysis (PD) patients. Tolvaptan was administered in 15 PD patients (15 mg daily). Urine volume, body weight, and blood pressure were monitored Urinary excretion of urea nitrogen Na+, the osmolality of plasma and urine, and peritoneal and renal Kt/V were analyzed before and after tolvaptan treatment. In 11 of 15 patients, urine volume increased to more than 400 mL daily. A significant increase in diluted urine was observed, as indicated by a reduction in the specific gravity or osmolality of urine (or both). Urinary excretion of urea nitrogen, and Na+ was significantly increased Increases in renal Kt/V were observed, but peritoneal Kt/V was unchanged. Singnificant increase in creatinine clearance was also observed These data suggest that tolvaptan not only stimulates water diuresis, but also natriuresis, without reducing RRF in PD patients. Hence, tolvaptan could be a beneficial tool for the control of body fluid and maintenance of RRF in PD patients.

The proportion of elderly people requiring renal replacement therapy has been increasing in Japan. Although several studies have shown the benefits of peritoneal dialysis (PD) in the elderly, few have reported on outcomes, including prognosis, in elderly PD patients, especially those more than 80 years of age. The purpose of the present study was to evaluate clinical outcomes in elderly (more than 80 years of age) PD patients. We retrospectively evaluated the medical records of elderly PD patients who commenced PD between 2007 and 2011. The frequency of perioperative complications, rate of PD-associated peritonitis, technique survival, overall survival, and utilization of nursing-care insurance systems were investigated as clinical outcomes. The 12 patients eligible for this study (7 men, 5 women; mean age: 85 +/- 3 years) had a median duration of follow-up of 1.2 years (interquartile range: 0.65-1.74 years). Perioperative complications were not observed in any of the patients. The frequency of PD-associated peritonitis was 1 episode in 56 months. During follow-up, 6 patients died, and 3 patients switched to hemodialysis because of tunnel infection or lack of family support. The overall survival rate at 12 months was 83%. Nursing-care insurance was used by 63% of patients. In elderly patients, it is important to predict the potential short-term issues at the initiation of PD to facilitate implementation of social services, such as home-visit nursing-care services, at the time of worsening general condition.

The case documented here represents the longest course of continuous-flow peritoneal dialysis (PD) reported in the literature. A 61-year-old man with hepatorenal syndrome type 1 and ascites presented with hypotension and bright red blood per rectum and was found to be in acute renal failure with severe anemia. Continuous-flow PD was initiated, and the patient improved clinically. The patient died of a jejunal bleed 8 months later, before discharge. Acute PD or continuous-flow PD is a viable alternative in the setting of hemodynamic instability and ascites, can be used as a chronic modality, and addresses many of the weaknesses of continuous ambulatory and automated PD.

Urgent-start peritoneal dialysis (PD) can be defined as initiation of PD within 2 weeks of catheter insertion. Urgent-start PD can be offered to patients who are referred late to a nephrologist and who would typically be initiated on hemodialysis with a temporary vascular access. An urgent-start PD capability requires expedited options education, catheter placement, unique change in the PD unit infrastructure, and new processes of care. This report describes the urgent-start PD program established by a nephrology private practice in the United States. Operational aspects of the program and initial clinical results are described.

Peritoneal dialysis (PD) patients are often volume-expanded and have higher-than-normal blood pressure (BP) levels. In the present study, we aimed to investigate the role of fluid balance and salt intake for BP control in our PD patients. The study included 37 patients undergoing PD and having complete data for 3 consecutive months. Patients were allocated to one of two groups based on measured BP in the preceding 3 months: hypertensive patients (BP > 140/90 mmHg) and normotensive patients (did not meet the hypertensive BP criteria). Volume status was evaluated by bioimpedance analysis. The 37 patients (18 women, 19 men) had a mean age of 46.4 years. The hypertensive and normotensive groups included 17 and 20 patients respectively. Sex, age, and time on PD were similar between the groups. Weight (77.3 +/- 20.3 kg vs. 64.5 +/- 9.8 kg, p < 0.05), total sodium load (2649.2 +/- 621.9 mmol vs. 2272.4 +/- 511.9 mmol, p < 0.05), daily total sodium removal (160.5 +/- 74.4 mmol vs. 112.1 +/- 48.0 mmol, p < 0.05), extracellular water (19.4 +/- 4.3 L vs. 16.4 +/- 3.5 L, p < 0.05), and normalized extracellular water (11.6 +/- 1.9 L vs. 10.1 +/- 1.8 L, p < 0.05) were all significantly higher in the hypertensive group. Despite higher fluid and sodium removal, hypertensive patients were more hypervolemic than normotensive patients. Increasing fluid and salt removal by peritoneal ultrafiltration results in an increased financial burden and also causes serious clinical problems. Restricting fluid and salt intake is an alternative and safer strategy to maintain good fluid balance.

Although peritoneal dialysis (PD) has been recommended for initial dialysis therapy, a larger proportion of patients with end-stage renal disease choose hemodialysis (HD) instead. Several previous studies comparing the outcomes of these two therapies, including survival rates and cardiovascular events, have not clearly demonstrated the superiority of one over the other. Our recent study indicated that, compared with HD or PD alone, renal replacement therapy with HD and PD in combination prolongs survival and reduces cardiovascular events. However, the use of combination dialysis therapy is not widely accepted. We set out to analyze the efficacy of combination dialysis therapy with PD and HD in patients who started with PD as initial dialysis therapy. Our single-center retrospective cohort study included 401 patients (165 women, 236 men; 61 +/- 12 and 62 +/- 9 years of age respectively) who started PD during 1995-2005. Chart and electronic databases were used to obtain information on the course of dialysis therapy, including mortality and cardiovascular events. Treatment with HD and PD in combination was used in 103 patients. During 5 years of follow-up after the start of PD, 80 patients died. We observed no differences in cumulative mortality between the men (49, 200%) and women (31, 18%) and no difference in the cumulative incidence of catheter removal for various reasons (35% vs. 31%). There was a significant difference (p < 0.05) in the time of HD start between men and women. In men on PD, HD therapy was started 22 +/- 2 months after the start of PD; in women, it was started 38 +/- 7 months after PD start. Although women have a survival advantage in both the general and the dialysis patient population, women on PD experience mortality similar to that in men. The reasons for those findings have not been fully explained. The present analysis suggests that an early start to HD therapy will prolong the survival of patients on PD, especially men.

A broad consensus has not been reached on the appropriate timing for cessation of peritoneal dialysis (PD). Decreasing urine volume, repeated and refractory peritonitis, and deterioration of the peritoneal membrane are major reasons to stop PD. Also, the link between length of time on PD and encapsulating peritoneal sclerosis (EPS) should be an additional concern. The aim of the present study was to investigate patients who had been on continuous ambulatory PD (CAPD) for a long time. All patients undergoing CAPD at our kidney center for more than a decade from January 1990 to September 2011 were included in the study. Among more than 436 CAPD patients, 11 met the inclusion criteria. Their mean PD duration was 12.3 +/- 3.1 years. Mean age at CAPD introduction had been 46.0 +/- 10.1 years. All patients had nondiabetic nephropathy as the underlying cause of their end-stage renal disease. At least 2 of the 11 had developed EPS, and 1 had subsequently died from EPS. Patients on prolonged CAPD for more than a decade are still rare. The CAPD modality may be continued if it is efficiently maintained within an acceptable level, but EPS remains a serious complication of prolonged PD.

Prednisolone and other glucocorticosteroids are used by some peritoneal dialysis patients because of underlying diseases such as peritonitis. Although corticosteroids are potent inhibitors of various processes during inflammation, their influence on the transport properties of peritoneum is little known. Our study investigated the influence of prednisolone (0.001 g/dL) on glucose (1.8 g/dL) and uric acid (0.02 g/dL) transfer across isolated parietal peritoneum taken from the anterior abdominal wall of white Hyplus 59 rabbits and placed inside a modified Ussing-type chamber. Values for transfer from the interstitial (I) to the mesothelial (M) side of membrane (I-->M) and in the opposite direction (M-->I) were calculated using the mathematical model of mass transport and are expressed as a coefficient of diffusive permeability [P (in centimeters per second)]. Four separate series of experiments were done. In the first and second series, we respectively examined glucose transport under control conditions (for 120 minutes) and then before (15-60 minutes) and after (75-120 minutes) introduction of prednisolone on the M side of the membrane. In the third and fourth series, similar studies of uric acid transfer were done. In the control (first and third) series, the stability of bidirectional transport for solute of interest was observed. The values of P +/- standard error of the mean (all x0.0001) for I-->M and M-->I transfer of glucose were, respectively, 2.489 +/- 0.329 cm/s and 2.259 +/- 0.493 cm/s. In the case of uric acid, the transport values were lower and amounted 1.936 +/- 0.324 cm/s and 1.895 +/- 0.596 cm/s for I-->M and M-->I respectively. Application of prednisolone on the M side of membrane lowered bidirectional transfer of glucose across peritoneal membrane by a mean of 73% (p < 0.02) and transport of uric acid by a mean of 19% (p < 0.003). These results show that, in vitro, prednisolone lowers glucose and uric acid transport across the peritoneal membrane, modifying the transfer dynamics of glucose to a greater extent. These observations may have clinical importance, especially in patients with disorders of peritoneal permeability, diabetes, and hyperuricemia.

During the past several decades, the conventional management of peritoneal dialysis (PD) patients undergoing elective abdominal surgery required a transition to hemodialysis on a temporary basis. In recent years, that protocol has been challenged by various authors who successfully repaired hernias in such subjects without interruption of their PD modality. However, that new approach was reserved for abdominal wall procedures and was not used for intra-abdominal surgery. The rapid evolution of laparoscopic surgery and the development and refinement of minimally invasive surgical techniques have revolutionized the field of surgery by providing superior outcomes for an ever-increasing list of indications including morbid obesity. The present study, the first of its kind involving elective intra-abdominal surgery, sought to determine the safety of uninterrupted PD therapy in morbidly obese patients with stage 6 chronic kidney disease undergoing laparoscopic bariatric surgery as a precursor to transplantation.

The role of peritoneal dialysis (PD) in the treatment of end-stage renal disease in elderly patients remains unclear. In the United States, PD is used only to a limited extent in that population. There are concerns about technique failure, including physical and psychosocial limitations and the risks of peritonitis. Thus, we retrospectively reviewed our 22 years of experience with patients 75 years of age and older who started on PD. Basic demographic data were collected, and mortality, technique failure, and peritonitis rates were determined. Quality of life (QOL) was assessed using the SF-36 questionnaire, a global QOL assessment, and a depression questionnaire. Among the 235 patients identified (mean age: 79 +/- 4 years; 51% white; 49% female; mean time on PD: 15.8 +/- 11.5 months), technique failure rates at 12 months were not significantly different for the patients 75 years of age older compared with the patients less than 75 years of age. Mortality rates were significantly higher in elderly patients. The peritonitis rate in patients 75 years of age and older was 1 episode in 23.6 patient-months compared with 1 episode in 23 patient-months in younger patients. The most common gram-positive organisms isolated were Staphylococcus epidermidis (38%0) and S. aureus (50%); gram-negative organisms accounted for 22%, and yeasts, 5% of peritonitis episodes. Reasons for transfer to hemodialysis included psychosocial problems (42%) and peritonitis (25%). Not surprisingly, physical component scores on the SF-36 were lower in the older than in the younger patients, but mental component scores on the SF-36 were slightly better in older than in younger patients, and global QOL and depression scores were not different between the groups. Our data suggest that PD is a reasonable modality for elderly patients.